Hyftor

Sirolimus, the active ingredient in Hyftor, is an mTOR inhibitor presented as a topical formulation for cutaneous use. It modulates immune activity and cell proliferation to treat selected skin conditions. GNH USA supplies Hyftor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, dermatology clinics and pharmacies worldwide.

Sirolimus acts on the mTOR pathway and is employed for several immunologically mediated conditions. - Tuberous sclerosis complex – facial angiofibromas: reduces size, redness and number of lesions. - Organ transplantation – prophylaxis of graft rejection: suppresses T‑cell activation to prevent rejection. - Lymphangioleiomyomatosis: slows disease progression by inhibiting abnormal cell growth.

Sirolimus may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Local skin irritation: redness, itching or burning at the application site. - Mouth ulcers: painful sores in the oral cavity. - Hyperlipidaemia: elevated cholesterol or triglyceride levels. - Headache: mild to moderate intensity. - Nausea: occasional digestive discomfort.

Serious or Rare Side Effects: - Infections: increased susceptibility to bacterial, viral or fungal infections. - Pneumonitis: inflammation of lung tissue presenting with cough or shortness of breath. - Renal impairment: reduced kidney function detectable by laboratory tests. - Hematologic abnormalities: anemia, leukopenia or thrombocytopenia.

When using Hyftor, consider the following safety measures. - Monitor blood counts: regular laboratory tests to detect hematologic changes. - Assess lipid profile: periodic cholesterol and triglyceride measurements. - Screen for infections: watch for signs of bacterial, viral or fungal disease. - Evaluate renal function: check serum creatinine and eGFR before and during therapy. - Avoid use in severe hepatic impairment: dose adjustment may be required. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Sirolimus can interact with several drug classes, influencing its concentration and effect.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may cause toxic sirolimus levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): can reduce efficacy by lowering drug exposure. - P‑glycoprotein inhibitors (e.g., verapamil): increase systemic exposure.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, requiring INR monitoring. - Statins (e.g., simvastatin, lovastatin): increased risk of myopathy; consider dose reduction or alternative lipid‑lowering agents. - Vaccines (live attenuated): potential for reduced vaccine efficacy or infection; assess risk‑benefit.